- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Muscle hypotonia.
Displaying page 1 of 1.
EudraCT Number: 2007-005010-40 | Sponsor Protocol Number: 30082007 | Start Date*: 2008-03-13 | |||||||||||
Sponsor Name:Univ.-Prof. Dr. Volker Wenzel | |||||||||||||
Full Title: Arginin Vasopressin im fortgeschrittenen vasodilatorischen Schock: Ein Dosisvergleich 2 vs. 4 IU/h | |||||||||||||
Medical condition: 5. Einschlusskriterien 5.1. Patienten mit vasodilatorischem Schock aufgrund: a) Sepsis [Definitionen gemäss den Empfehlungen der ACCP/SCCM (12)] b) SIRS [Definitionen gemäss den Empfehlungen der ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005475-41 | Sponsor Protocol Number: MLX | Start Date*: 2014-11-05 |
Sponsor Name:UZ Brussel | ||
Full Title: Sulfamethoxazole treatment of primary PREPL deficiency | ||
Medical condition: Hypotonia-cystinuria syndrome and isolated PREPL deficiency. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002164-41 | Sponsor Protocol Number: END-GH-2017 | Start Date*: 2017-07-03 | |||||||||||
Sponsor Name:Fundació Parc Taulí | |||||||||||||
Full Title: Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by functional magnetic resonance imaging (fMRI) and its relation to muscle strenght and body composition. | |||||||||||||
Medical condition: Patients with Prader-Willi Syndrome (SPW) with Growth hormone deficit. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001235-27 | Sponsor Protocol Number: AVXS-101-CL-101 | Start Date*: 2020-04-06 |
Sponsor Name:AveXis, Inc. | ||
Full Title: Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101 | ||
Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-001147-51 | Sponsor Protocol Number: COMPIS | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:Västra götalandsregionen | |||||||||||||
Full Title: Congenital myopathy intervention study | |||||||||||||
Medical condition: Congenital myopathy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020386-24 | Sponsor Protocol Number: TRO19622CLEQ1275-1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients. | |||||||||||||
Medical condition: Spinal Muscular Atrophy (type 2 or type 3 non ambulant patients aged 3-25 years) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) NL (Completed) BE (Completed) DE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000067-16 | Sponsor Protocol Number: AMO-02-MD-2-001 | Start Date*: 2016-04-20 | |||||||||||
Sponsor Name:AMO Pharma Ltd. | |||||||||||||
Full Title: A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy | |||||||||||||
Medical condition: Treatment of adolescent and adult congenital and juvenile onset myotonic dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004830-14 | Sponsor Protocol Number: UX007-CL201 | Start Date*: 2014-02-26 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: An Open-Label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000778-40 | Sponsor Protocol Number: BP39056 | Start Date*: 2017-01-05 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN INFANTS WITH TYPE1 SPINAL MUSCULAR ATROPHY | |||||||||||||
Medical condition: Type 1 Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) IT (Completed) BE (Completed) FR (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004623-23 | Sponsor Protocol Number: AMO-02-MD-2-003 | Start Date*: 2018-11-19 | ||||||||||||||||
Sponsor Name:AMO Pharma Ltd | ||||||||||||||||||
Full Title: A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents with Congenital Myotonic Dystrophy | ||||||||||||||||||
Medical condition: Treatment of child and adolescent congenital myotonic dystrophy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
